Human Papillomavirus Vaccines

Schmiedeskamp, Mia R; Kockler, Denise R

doi:10.1345/aph.1g723

Cited by 48 publications

(32 citation statements)

References 40 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cervarix is an HPV16/ 18 L1 virus-like particle vaccine that offers complete protection against HPV16-and 18-associated precancerous lesions as well as substantial protection against types 45 and 31 (Harper et al 2006). Gardasil is a quadrivalent vaccine made of the major capsid protein (L1) of high-risk HPV types 16 and 18, and low-risk types 6 and 11, which has been found to prevent 100% CIN2/3 and adenocarcinoma in situ associated with HPV16 and 18 infections (Schmiedeskamp and Kockler 2006). These vaccines may prove to be effective against a majority of cervical cancers, but may not benefi t women infected with rarer HPV types.…”

Section: Discussionmentioning

confidence: 99%

Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India

et al. 2008

View full text Add to dashboard Cite

Cervical cancer is a leading cause of cancer-related deaths among women in India. Human papillomavirus (HPV) infection is the causative agent of cervical cancer; and infection with the high-risk genotypes, predominantly HPV16 and 18,is the biggest risk factor. Vaccines targeting HPV16 and 18 have been found to confer protection in large- scale clinical trials.HPV genotyping has traditionally been carried out to screen the population "at risk" using indirect methods based on polymerase chain reaction (PCR) using consensus primers combined with various DNA hybridization techniques,and often followed by the sequencing of candidate products.Recently,a high-throughput and direct method based on DNA sequencing has been described for HPV genotyping using multiplex pyrosequencing. We present a pilot study on HPV genotyping of cervical cancer and non-malignant cervical samples using multiplex pyrosequencing. Using genomic DNA from cell lines,cervical biopsies,surgical tissues or formalin-fixed,paraffin- embedded tissue samples,we could successfully resolve 6 different HPV types out of the 7 tested,with their prevalence found to be in agreement with earlier reports. We also resolved coinfections with two different HPV types in several samples. An HPV16 genotype with a specific and recurrent sequence variation was observed in 8 cancer samples and one non-malignant sample. We find this technique eminently suited for high-throughput applications,which can be easily extended to large sample cohorts to determine a robust benchmark for HPV genotypes prevalent in India.

show abstract

Section: Discussionmentioning

confidence: 99%

Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India

et al. 2008

View full text Add to dashboard Cite

show abstract

“…1 Well-documented evidence exists showing that cervical cancer is related to persistent Human Papillomavirus (HPV) infection. [2][3][4][5] Using sensitive Polymerase Chain Reaction (PCR) techniques, HPV-DNA is detected in almost 100% of invasive cervical cancers. 4,[6][7][8][9][10][11][12] The highest prevalence of HPV-induced cervical preneoplastic changes occurs in the third decade, 13 while the mean age of invasive carcinoma occurs in the middle of the sixth decade, 14 suggesting a prolonged latent phase of genital infection before the onset of malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Cervical Human Papillomavirus in transplanted Italian women: A long-term prospective follow-up study

Origoni

Stefani

Dell’Antonio

et al. 2011

Journal of Clinical Virology

View full text Add to dashboard Cite

“…[6] Cervarix, a bivalent vaccine, targets HPV 16 and HPV 18, which are responsible for 70% of cervical cancers. [28] All studies showed HPV-type speciÞ c protection; Cross-protection was noted in one study. [26] ; The age of women in these studies ranged from 15 to 26 years Gardasil, a quadrivalent vaccine, also targets HPV 16 and HPV 18, plus the HPV types 6 and 11 responsible for more than 80% of genital warts.…”

Section: Emerging Hpv Vaccines Emerging Hpv Vaccinesmentioning

confidence: 96%

Vaccines for human papillomavirus infection: A critical analysis

Nath¹,

Thappa²

2009

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

This article takes a critical look at the pros and cons of human papillomavirus (HPV) vaccines. There is enough evidence to suggest that the prophylactic vaccines are efficacious in preventing various benign and malignant conditions (including cervical cancers) caused by HPV. Even though the vaccine is costly, hypothetical analysis has shown that HPV vaccination will be cost effective in the long run. Therapeutic HPV vaccines used to treat established disease are still undergoing evaluation in clinical studies, and results seem to be encouraging. Although several countries have started mandatory vaccination programs with the prophylactic HPV vaccines, conservatives have voiced concerns regarding the moral impact of such vaccination programs.

show abstract

Human Papillomavirus Vaccines

Cited by 48 publications

References 40 publications

Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India

Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India

Cervical Human Papillomavirus in transplanted Italian women: A long-term prospective follow-up study

Vaccines for human papillomavirus infection: A critical analysis

Contact Info

Product

Resources

About